Multivariate independent prognostic factors in endometrial carcinoma: A clinicopathologic study in 181 patients: 10 Years experience at the Department of Obstetrics and Gynecology of the Mainz University

International Journal of Gynecological Cancer

Volumn 13, Issue 2, 2003, Pages 197-203

  Steiner, Eric ^a   Eicher, O ^a   Sagemuller J ^a   Schmidt, M ^a   Pilch, H ^a   Tanner, B ^a   Hengstler, J G ^a   Hofmann, M ^a   Knapstein, P G ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Endometrial carcinoma; Multivariate prognostic factors

Indexed keywords

PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CLINICAL FEATURE; ENDOMETRIUM CARCINOMA; FEMALE; HOSPITAL DEPARTMENT; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR CLASSIFICATION; ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; AGED; DIABETES MELLITUS; ENDOMETRIUM TUMOR; GERMANY; MEDICAL RECORD; METAPLASIA; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ADENOSQUAMOUS; DIABETES MELLITUS; ENDOMETRIAL NEOPLASMS; FEMALE; GERMANY; HUMANS; LYMPHATIC METASTASIS; MEDICAL RECORDS; METAPLASIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0038306995     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13021.x     Document Type: Article

References (27)

1. Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W. MIB-1 in endometrial carcinoma: Prognostic significance with 5-follow-up. Gynecol Oncol 1999;75:432-6.
2. Nielsen AL, Nyholm HC, Engel P. Expression of MIB-1 and AGNOR morphology in endometrial adenocarcinoma of endometroid type. Int J Gynecol Pathol 1994;13:37-44.
3. Bell JG, Minnick A, Reid GC, Judis J, Brownell M. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma. Gynecol Oncol 1997;66:388-92.
4. Orr JW, Orr PF, Taylor PT. Surgical staging endometrial cancer. Clin Obstet Gynecol 1996;39:656-68.
5. Mammoliti S, Bruzzone M, Chiara S. Clinical stage I and II endometrial carcinoma: multivariate analysis of prognostic factors. Anticancer Res 1992;12:1415-8.
6. Vecek N, Nola M, Marusic M et al. Prognostic value of steroid hormone receptors concentration in patients with endometrial cancer. Acta Obstet Gynecol Scand 1994;73:730-3.
7. Lindahl B, Ranstam J, Norgren A, Willen R. Identification of high-risk groups in endometrial carcinoma stage I-II. Anticancer Res 1995;15:1095-100.
8. Leminen A, Forss M, Lehtovirta P. Endometrial adenocarcinoma with clinical evidence of cervical involvement: Accuracy of diagnostic procedures, clinical course and prognostic factors. Acta Obstet Gynecol Scand 1995;74:61-6.
9. Ehrlich CE, Young PCM, Stehmann FB, Sutton GP, Alford WM. Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 1988;158:796-807.
10. Wagenius G, Strang P, Bergström R, Stendahl U, Tribukait B. Prognostic indices in endometrial adenocarcinoma stages I and II. Anticancer Res 1991;11:2137-42.
11. Kadar N, Malfetano JH, Homesley HD. Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy. Obstet Gynecol 1992;80:655-9.
12. Creasman WT. Prognostic significance of hormone receptors in endometrial carcinoma. Cancer 1993;60:2035-41.
13. Creasman WT. Announcement. FIGO stages 1988 revisions. Gynecol Oncol 1989;35:125-7.
14. Scully RE, Poulson H, Sobin LH. International Classification and Histologic Typing of Female Genital Tract Tumours. Springer: New York, 1994.
15. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, ed. Blaustein's Pathology of the Female Genital Tract, 4th edn. Springer: New York, 1994, 439-86.
16. Sevin B-U, Angioli R. Uterine Corpus: Multimodality Therapy in Gynecologic Oncology. Thieme: New York, 1996.
17. Kleine W, Maier T, Geyer H, Pfleiderer H. Estrogen and progesterone receptors in endometrial carcinoma and their prognostic significance. Gynecol Oncol 1990;38:59-65.
18. Gambrell RD, Bagnell CA, Greenblatt RB. Role of estrogens and progesterone in etiology and prevention of endometrial cancer: review. Am J Obstet Gynecol 1983;15:696-707.
19. Wynder EL, Escher GC, Mantel N. An epidemilocical investigation of cancer of the endometrium. Cancer 1966;19:489.
20. KauppilaA, Grönroos M, Niemminen U. Clinical outcome in endometrial cancer. Obstet Gynecol 1982;60:473-80.
21. Eifel PJ, Ross J, Hendrickson M, Cox RS, Kempson R, Martinez A. Adenocarcinoma of the endometrium. Cancer 1983;52:1026-31.
22. Tabernero LM, Alonso MC, Ojeda B et al. Endometrial cancer stages I and II. Eur J Gynecol Oncol 1995;16:18-25.
23. Malkasian GD, Annegers JF, Fountain KS. Carcinoma of the endometrium stage I. Am J Obstet Gynecol 1980;136:872-83.
24. Chambers JT, MacLusky N, Eisenfield A, Kohorn EI, Lawrence R, Schwartz PE. Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer. Gynecol Oncol 1988;31:65-81.
25. Nyholm HCJ, Christensen IJ, Nielsen AL. Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 1995;59:347-51.
26. Morris PC, Anderson JR, Anderson B, Buller RE. Steroid hormon receptor content and lymph node status in endometrial cancer. Gynecol Oncol 1995;56:406-11.
27. Park D-W, Ryu H-E, Choi D-S, Park Y-H, Chang K-H, Min CK. Localization of matrix mettalloproteinase on endometrial cancer cell invasion in vitro. Gynecol Oncol 2001;82:442-9.